225 related articles for article (PubMed ID: 30963691)
21. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
Maier A; Peille AL; Vuaroqueaux V; Lahn M
Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
[TBL] [Abstract][Full Text] [Related]
22. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.
Santini V; Valcárcel D; Platzbecker U; Komrokji RS; Cleverly AL; Lahn MM; Janssen J; Zhao Y; Chiang A; Giagounidis A; Guba SC; Gueorguieva I; Girvan AC; da Silva Ferreira M; Bhagat TD; Pradhan K; Steidl U; Sridharan A; Will B; Verma A
Clin Cancer Res; 2019 Dec; 25(23):6976-6985. PubMed ID: 31481511
[TBL] [Abstract][Full Text] [Related]
23. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
25. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481241
[TBL] [Abstract][Full Text] [Related]
26. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
[TBL] [Abstract][Full Text] [Related]
27. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
Kudo M; Hatano E; Ohkawa S; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Kaneko S; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Tsuji A; Kudo T; Shimada M; Osaki Y; Tateishi R; Sugiyama G; Abada PB; Yang L; Okusaka T; Zhu AX
J Gastroenterol; 2017 Apr; 52(4):494-503. PubMed ID: 27549242
[TBL] [Abstract][Full Text] [Related]
28. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
29. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Kim BK; Ahn SH; Seong JS; Park JY; Kim DY; Kim JK; Lee DY; Lee KH; Han KH
Liver Int; 2011 Mar; 31(3):369-76. PubMed ID: 21083802
[TBL] [Abstract][Full Text] [Related]
30. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
Rimassa L; Abbadessa G; Personeni N; Porta C; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; De Toni EN; Weiss A; Miles S; Gasbarrini A; Lencioni M; Lamar ME; Wang Y; Shuster D; Schwartz BE; Santoro A
Oncotarget; 2016 Nov; 7(45):72622-72633. PubMed ID: 27579536
[TBL] [Abstract][Full Text] [Related]
31. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Kelley RK; Verslype C; Cohn AL; Yang TS; Su WC; Burris H; Braiteh F; Vogelzang N; Spira A; Foster P; Lee Y; Van Cutsem E
Ann Oncol; 2017 Mar; 28(3):528-534. PubMed ID: 28426123
[TBL] [Abstract][Full Text] [Related]
32. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
[TBL] [Abstract][Full Text] [Related]
33. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
34. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Br J Cancer; 1997; 76(2):244-50. PubMed ID: 9231926
[TBL] [Abstract][Full Text] [Related]
35. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Br J Cancer; 1997; 75(10):1460-6. PubMed ID: 9166938
[TBL] [Abstract][Full Text] [Related]
37. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Shao YY; Liu TH; Hsu C; Lu LC; Shen YC; Lin ZZ; Cheng AL; Hsu CH
Liver Int; 2019 Nov; 39(11):2184-2189. PubMed ID: 31400295
[TBL] [Abstract][Full Text] [Related]
38. Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Lee S; Kim BK; Kim SU; Park JY; Kim do Y; Ahn SH; Han KH
J Hepatocell Carcinoma; 2015; 2():39-47. PubMed ID: 27508193
[TBL] [Abstract][Full Text] [Related]
39. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
[TBL] [Abstract][Full Text] [Related]
40. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
Vora SR; Zheng H; Stadler ZK; Fuchs CS; Zhu AX
Oncologist; 2009 Jul; 14(7):717-25. PubMed ID: 19581525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
